Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027 Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027
Covered in this story
What has happened since
- Sanofi is up 1.5% since this was published, 5 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $SAN.PA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Sanofi →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.